Skip to content

A clinical trial to evaluate the efficacy of electroacupuncture on mild cognitive impairment

A randomized, outcome assessor blinded, parallel- arm, single center investigator initiated trial to evaluate the efficacy and safety of electroacupuncture stimulator on mild cognitive impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003415
Enrollment
36
Registered
2019-01-04
Start date
2018-11-29
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : CCR : Rehacom cognitive rehabilitation once(30 minutes) per day, 3 days per week (excluding Saturday and Sunday) for 8 weeks. computer-based cognitive rehabilitation group : Rehacom c
30 minutes, EA
30 minutes) per day, 3 days per week (excluding Saturdayand Sunday) for 8 weeks.

Sponsors

Dongshin University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants meeting all of the following criteria will be included in this trial. The inclusion criteria are as follows: 1) participants(males and females) aged 55 to 85 ; 2) participants who meet the Peterson diagnostic criteria for MCI, with memory impairments for at least 3 months; 3) Score in K-MMSE was 20-23; 4) Score in MoCA-K was 0-22;5) fluency in language sufficient to reliably complete all study assessment; 6) voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: Participants with a poor general condition and those who are not fit for electroacupuncture will be excluded. The exclusion criteria are as follows: 1) diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Disorders- ?; 2) history of brain structure lesions which may cause cognitive impairment(e.g., traumatic brain injury, stroke, intracranial space-occupying lesions, congenital mental retardation); 3) complicated by cancer and serious diseases of the cardiovascular, cerobrovascular, liver, and kidney; 4) who had been treated with alcohol or drug dependency, mental diseases(e.g., schizophrenia, serious anxiety, and depression) in the past six months in the past six months; 5) Currently under treatment for MCI(e.g., medication, acupuncture, and cognitive training); 6) who have difficulties in assessment due to visual and hearing impairments; 7) who are not fit for electroacupuncture (e.g., blood clotting abnormalitiessuch as hemophilia, infection of the head skin, and pacemaker attached); 8) concurrent participation in other clinical trials

Design outcomes

Primary

MeasureTime frame
Alzheimer's Disease Asessment Scale-Korean version-cognitive subscale (ADAS-K-cog)

Secondary

MeasureTime frame
Korean version of the Montreal Cognitive Assessment(MoCA-K);Center for Epidemiological Studies-Depression Scale( CES-D);Korean Activities of Daily Living( K-ADL), Korean Instrumental Activities of Daily Living( K-IADL);European Quality of Life Five Dimension. Five Level Scale(EQ-5D-5L)

Countries

Korea, Republic of

Contacts

Public ContactJae Hong Kim

Dongshin University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 2, 2026